CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	138.1	101.21	53.16	37.31	68.43
Revenue Growth (YoY)	36.45%	90.38%	42.48%	-45.47%	154.36%
Gross Profit	138.1	101.21	53.16	37.31	68.43
Selling, General & Admin	29.73	30.02	40.45	39.16	36.03
Research & Development	83.38	77.68	106.55	114.19	112.94
Operating Expenses	113.11	107.7	147	153.35	148.97
Operating Income	25	-6.48	-93.84	-116.04	-80.54
Interest & Investment Income	7.14	9.84	1.68	0.26	1.84
Currency Exchange Gain (Loss)	-0.04	-0.03	0.34	-0.08	-0.03
EBT Excluding Unusual Items	32.09	3.32	-91.82	-115.87	-78.73
Merger & Restructuring Charges	-	-	-7.5	-	-
Pretax Income	32.09	3.32	-99.32	-115.87	-78.73
Income Tax Expense	0.22	3.89	-	-	-13.91
Net Income	31.87	-0.57	-99.32	-115.87	-64.82
Net Income to Common	31.87	-0.57	-99.32	-115.87	-64.82
Shares Outstanding (Basic)	84	74	66	64	46
Shares Outstanding (Diluted)	85	74	66	64	46
Shares Change (YoY)	14.82%	12.27%	2.48%	39.01%	1.79%
EPS (Basic)	0.38	-0.01	-1.51	-1.81	-1.40
EPS (Diluted)	0.38	-0.01	-1.51	-1.81	-1.40
Free Cash Flow	-86.54	-56.88	-112.53	-120.64	2.95
Free Cash Flow Per Share	-1.02	-0.77	-1.71	-1.88	0.06
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	18.10%	-6.41%	-176.50%	-311.00%	-117.70%
Profit Margin	23.08%	-0.56%	-186.82%	-310.54%	-94.73%
Free Cash Flow Margin	-62.66%	-56.19%	-211.67%	-323.33%	4.31%
EBITDA	26.76	-4.31	-91.39	-113.34	-77.97
EBITDA Margin	19.38%	-4.26%	-171.91%	-	-113.94%
D&A For EBITDA	1.77	2.18	2.44	2.71	2.57
EBIT	25	-6.48	-93.84	-116.04	-80.54
EBIT Margin	18.10%	-6.41%	-176.50%	-	-117.70%
Effective Tax Rate	0.70%	117.12%	-	-	-

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q